TARGETED DIAGNOSTICS

Cancer is a class of diseases in which a group of cells display uncontrolled growth, invasion and sometimes spreading to other locations in the body via lymph or blood. This growth is caused by modification of the DNA, called mutations. Since the mutation can occur in different genes tumors respond differently to certain treatments, let it be radiation or chemotherapy or application of new-generation drugs. The treatment of cancer is highly dependent on several factors: the time of diagnosis, the progression, the location of the tumor and as mentioned above, the mutation status of tumor cells. In many cases, the surgery itself is sufficient, but chemotherapy or radiation therapy, targeted drug therapy is often added into.

 

CONTACT US

For further informations and consultation please contact us diagnosztika@kps.hu

 

In order to offer the most appropriate, targeted therapy to the patient, we must determine the mutations of oncogenes in the tumor tissue. We provide diagnosis of drug targets during our molecular diagnostics. It can be selected after the determination of the molecular state of genes which is the most effective treatment for the patient, because in some cases, a mischosen targeted therapy may prove not only ineffective, but also result in unwanted side effects, and in some cases, the patient's condition may even worsen.

 

The list of required test are included in the safety information of some drugs, in other cases Health Insurance Fund prescribes molecular pathological studies. However, additional genes, biomarkers are also available to help the oncologist to select the more successful, optimal treatment protocol for the patient. In the Molecular Pathology Laboratory of KPS not only required, but also further recommended examination of the proposed biomarkers are available, so the doctor can offer the best possible therapeutic approach in the light of molecular diagnosis.

 

 

Our publication has been released in Nature Reviews Drug Discovery

In July, Nature Reviews Drug Discovery will publish our CEO's paper about the chances of development of novel drug compounds and targeted therapy in the future. In the 1990s, the breast cancer drug trastuzumab (Herceptin; Genentech/Roche) — an antibody specific for human epidermal growth factor receptor 2 (HER2; also known as ERBB2) — was approved based on trials in which HER2 expression levels were used to select patients in clinical trials. This provided support for analogous efforts for drugs that target the epidermal growth factor receptor (EGFR). However, the development of these drugs, such as cetuximab (Erbitux; Bristol–Myers Squibb/Lilly) and gefitinib (Iressa; AstraZeneca), has revealed that EGFR expression is an insufficient and unreliable biomarker to select patients for EGFR-targeted therapies in both lung and colon cancer. Indeed, evidence on patient populations that are likely to respond to such therapies, on the basis of specific mutations in proteins of the targeted pathway, has only recently been clinically validated and incorporated into some of the drug labels. This article highlights lessons learned from the development of the first drugs targeting the EGFR family and discusses strategies to decrease the risk of failure in clinical development by more effectively integrating molecular diagnostics into anticancer drug discovery. More»


Further news

The benefit of science TODAY

The emergence of molecular-targeted medicine at the turn of the 21st century brought a breakthrough in the personalized treatment of tumors and inflammations, comparable only to the discovery of penicillin. At the turn of the nineteenth More»

Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine

BACKGROUND: Gastro-oesophageal reflux disease (GERD) can be associated with laryngo-respiratory symptoms (LRS) such as chronic cough, asthma or laryngeal symptoms. AIM: To analyse the long-term clinical course of LRS in a large population More»

Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures

Background: The growing use of imaging procedures in the United States has raised concerns about exposure to low-dose ionizing radiation in the general population. Methods: We identified 952,420 nonelderly adults (between 18 and 64 More»

Use and impact of early endoscopy in elderly patients with peptic ulcer hemorrhage: a population-bas

Background: Upper endoscopy performed within 1 day of presentation, or early endoscopy, has been proposed as an intervention to improve the efficiency and outcomes of care for patients with peptic ulcer hemorrhage. However, the More»

Forum

Gyulladásos bélbetegségek Sziasztok,Ja igen, Tihany!Majdnem
2010, Június 24. 16:28 Csizkat

Gyulladásos bélbetegségek hmm, azert az rendjen van,
2010, Június 20. 21:39 Richard

Gyulladásos bélbetegségek Ezek olyan dolgok, hogy
2010, Június 14. 09:55 chysh